Clinical trials researching the treatment of rare diseases ALS, HD, and MG are explored in this section to gain an overall view of the past and current state of clinical development. Over 1000 clinical trials have been registered on the US National Institutes of Health (NIH) clinical trial website over the last 10 years for these rare diseases. In terms of sheer number, ALS has the highest number of registered clinical trials, followed by HD and MG. Figure shows an oscillating curve for clinical trials of these rare disease, between the years 2013 to 2023. ALS clinical trials gradually increase over the years, while HD stayed more consistent. One note of interest is that the number of clinical trials for MG stay consistent through 2018 and then triple into 2019, maintaining consistency moving forward. One contributing factor to this surge is the US FDA approval of Solaris (eculizumab) in 2017, the first for MG, increasing industry-sponsored clinical research to monitor and develop new therapy options for patients with this rare disease. Further analysis of these rare disease clinical trials reveals that nearly half of all trials for the different indications are not phased (Figure ). The phase that contains the next largest group of trials is Phase II studies for ALS and HD and Phase III studies for MG. Nearly half of all clinical trials for ALS, HD, and MG have been completed (Figure ). The status with the next largest group of trials is the recruiting status, which is encouraging as new clinical trials are created and carried out to research the treatment of these rare diseases, offering hope to patients worldwide.